Listen Now

Host: Linda Bernstein, Pharm.D. The U.S. Food and Drug Administration issued an emergency use authorization, or EUA, for the Moderna COVID-19 vaccine. The second vaccination to achieve EUA designation, the Moderna vaccine will be distributed throughout the US for patients 18 years and older. In this episode of The Drug Report, Dr. Linda Bernstein discusses this newly-approved vaccine and how it compares to others. Published December 29, 2020

Host: Linda Bernstein, Pharm.D. The U.S. Food and Drug Administration announced its approval of Ebanga (Ansuvimab-zykl) for the treatment of the ebola virus infection in adults and children. To learn more about the second ebolavirus treatment to receive approval, Dr. Linda Bernstein walks us through this new drug. Published December 29, 2020

Host: Linda Bernstein, Pharm.D. As a growing number of pharmaceutical companies refuse to provide discounts to 340B hospitals for drugs dispensed at community-based pharmacies, a federal lawsuit is challenging the U.S. Department of Health and Human Services in order to fight for patient communities harmed by this refusal. On this episode of The Drug Report, Dr. Linda Bernstein dives into this lawsuit.

Host: Linda Bernstein, Pharm.D. The first vaccine to receive Emergency Use Authorization from the US Food and Drug Administration, this authorization allows the Pfizer-BioNTech COVID-19 vaccine to be distributed throughout the US. But what do we know about this vaccine? In this episode of The Drug Report, Dr. Linda Bernstein discusses the Pfizer-BioNTech COVID-19 vaccine. Published December 18, 2020

Host: Linda Bernstein, Pharm.D. A sedative commonly used in anesthesia, dexmedetomidine hydrochloride has been the subject of many news reports over the past few months. But most recently, the FDA announced approval for Aurobindo Pharma’s dexmedetomidine hydrochloride in 0.9% sodium chloride injection. In this episode of The Drug Report, Dr. Linda Bernstein reviews recent approvals of dexmedetomidine hydrochloride on initially intubated and mechanically ventilated patients. Published December 17, 2020

Host: Linda Bernstein, Pharm.D. Asthma remains a significant global health problem, and more than 25 million Americans suffer from it. How have the National Asthma Education and Prevention Program’s guidelines changed to help manage this chronic condition? In this episode of The Drug Report, Dr. Linda Bernstein reviews new guidelines on the management of asthma in adolescents and adults. Published December 10, 2020

Host: Linda Bernstein, Pharm.D. To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug. Published December 2, 2020

Host: Linda Bernstein, Pharm.D. Pfizer and BioNTech recently announced that their mRNA vaccine for the COVID-19 virus was 90 percent effective, and the companies plan to apply for Emergency Use Authorization. This episode of The Drug Report dives into this vaccine’s Phase 3 clinical trial and explores developments made by other companies in the search for a COVID-19 vaccine. Published November 30, 2020

Host: Linda Bernstein, Pharm.D. This episode of The Drug Report takes a look at a COVID-19 cocktail comprised of the coadministration of casirivimab and imdevimab, which has proven to decrease hospitalization and emergency room visits. Published November 30, 2020

Host: Linda Bernstein, Pharm.D. With the spread of the COVID-19 pandemic, fewer children have received a measles vaccination, and progress towards eliminating this disease has halted. How can pharmacists encourage more pediatric measles vaccinations? In this episode of The Drug Report, Dr. Linda Bernstein takes a look at the vast number of children globally who’ve yet to receive this vaccine. Published November 30, 2020

Host: Linda Bernstein, Pharm.D. The U.S. Food and Drug Administration has granted Eli Lilly and Company’s trial vaccine for COVID-19 an Emergency Use Authorization, or EUA. On this episode of The Drug Report, learn more about this monoclonal antibody and how the company plans on distributing it. Published November 30, 2020

Host: Linda Bernstein, Pharm.D. In light of the COVID-19 pandemic, the Centers for Disease Control and Prevention, or the CDC, plans to use pharmacies to increase access to the COVID-19 vaccine when it is ready for distribution. In this episode of The Drug Report, Linda Bernstein will explain the CDC’s recently-developed Vaccination Program Interim Playbook. Published November 17, 2020

Host: Linda Bernstein, Pharm.D. The Food and Drug Administration announced that Remdesivir is the first treatment for COVID-19 to receive their approval. To help us better understand this antiviral agent, Dr. Linda Bernstein discusses emerging studies uncovering the benefits and limitations of Remdesivir. Published November 6, 2020

Host: Linda Bernstein, Pharm.D. Join pharmacist Dr. Linda Bernstein as she highlights several articles from recent literature describing coagulopathies in severely ill COVID-19 patients in China. She explores the cause and effect theories behind these findings and whether the observed coagulopathies are due directly to the virus, the critically ill condition of the patient that predisposes them to thromboembolism, or some combination of the two. Published April 24, 2020

Host: Linda Bernstein, Pharm.D. The US Food and Drug Administration has authorized clinicians to prescribe chloroquine and hydroxychloroquine for hospitalized patients with COVID-19, despite warnings from scientific advisers that no randomized controlled trial has been conducted to support the drugs’ safety and efficacy in this population. Pharmacist Dr. Linda Bernstein takes us through the FDA’s decision process, the parameters of the issuance, and comments made by the experts on this emergency ruling. Published April 24, 2020

Host: Linda Bernstein, Pharm.D. The Drug Enforcement Administration (DEA) issued a new guidance for the issuance of oral Schedule II prescriptions in light of the COVID-19 pandemic and nationwide public health emergency. Pharmacist Dr. Linda Bernstein details the DEA’s temporary exceptions to the regulations to ease prescribing and dispensing of these controlled substances during this challenging time. Published April 24, 2020

Host: Linda Bernstein, Pharm.D. Tune in as pharmacist Dr. Linda Bernstein looks at a few of the novel approaches researchers all over the world are taking to conquer the novel coronavirus in addition to evaluating what these approaches may mean for today and potential viral mutations going forward. Published April 21, 2020

Host: Linda Bernstein, Pharm.D. Critical medicine shortages during the COVID-19 pandemic, particularly for drugs required to support patients on mechanical ventilation, is the focus of this episode of The Drug Report. Pharmacist Dr. Linda Bernstein describes the urgent appeals made by major healthcare organizations, related reports highlighting the serious impact of these shortages on fill rates for critical medicines, and progress being made at the federal level to remedy the situation. Published April 21, 2020

Host: Linda Bernstein, Pharm.D. Join pharmacist Dr. Linda Bernstein as she outlines the United States Health and Human Services’ authorization of licensed pharmacists to order and administer FDA-approved COVID-19 tests as well as the priority patient testing categories as set forth by the U.S. Public Health Service. Published April 21, 2020

Host: Linda Bernstein, Pharm.D. The World Health Organization (WHO) and partners recently announced it was launching an international clinical trial with the goal of generating significant worldwide data from thousands of patients to find the most effective treatments for COVID-19. Pharmacist Dr. Linda Bernstein brings you an update on the WHO SOLIDARITY trial, which will offer clinicians simplified procedures to enable even overloaded hospitals to participate. Published April 17, 2020